Heart, Lung and Circulation
Volume 15, Issue 5 , Pages 306-309 , October 2006

Carvedilol Reduces Aldosterone Release in Systolic Heart Failure

  • Anuradha Aggarwal, FRACP, PhD

      Affiliations

    • Cardiology Department, Royal Melbourne Hospital, Grattan Street, Parkville, Victoria, Australia
    • Corresponding Author InformationCorresponding author at: Cardiology Department, c/o Post Office, The Royal Melbourne Hospital, Parkville, Victoria 3050, Australia. Tel.: +61 3 93427133; fax: +61 3 93472808.
    • ,
  • James Wong, FRACP, PhD

      Affiliations

    • Cardiology Department, Royal Melbourne Hospital, Grattan Street, Parkville, Victoria, Australia
    • ,
  • Duncan J. Campbell, FRACP, PhD

      Affiliations

    • St. Vincent's Institute of Medical Research and the Department of Medicine, University of Melbourne, St. Vincent's Hospital, Fitzroy, Victoria, Australia

Received 21 March 2006 ,Revised 29 May 2006 ,Accepted 3 June 2006.

References 

  1. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodelling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol. 2000;35:569–582
  2. Buhler FR, Laragh JH, Baer L, Vaughan ED, Brunner HR. Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. New Engl J Med. 1972;287:1209–1214
  3. Campbell DJ, Aggarwal A, Esler M, Kaye D. Beta-blockers, angiotensin II, and ACE inhibitors in patients with heart failure. Lancet. 2001;358:1609–1610
  4. Pitt B, Zannad F, Remme WJ, Cody R, Castagigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New Engl J Med. 1999;341:709–717
  5. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. New Engl J Med. 2004;351:543–551
  6. Lawrence AC, Evin G, Kladis A, Campbell DJ. An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal-directed antisera: measurement of eight angiotensin peptides in human plasma. J Hypertens. 1990;8:715–724
  7. Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, et al. Development of a novel, N-terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl. 1999;230:177–181
  8. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl J Med. 2003;348:1309–1321
  9. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003;362:767–771
  10. Hansen PR, Rieneck K, Bendtzen K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunol Lett. 2004;91:87–91
  11. Fung JW, Yu CM, Yip G, et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin–angiotensin–aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol. 2003;92:406–410

PII: S1443-9506(06)00129-6

doi: 10.1016/j.hlc.2006.06.003

Heart, Lung and Circulation
Volume 15, Issue 5 , Pages 306-309 , October 2006

Article Tools

* Image Usage & Resolution